Abaloparatide Real-World Patient Experience Study

Deborah T Gold; Richard Weiss; Tammy Beckett; Chad Deal; Robert S Epstein; Andrew L James; Jacqueline M Kernaghan; Mahshid Mohseni; Michael Spiegel; Tamara Vokes; Jenna Roberts; Tom Bailey; Yamei Wang; Setareh A Williams

doi:10.1002/jbm4.10457

Abaloparatide Real-World Patient Experience Study

JBMR Plus. 2021 Feb 4;5(3):e10457. doi: 10.1002/jbm4.10457. eCollection 2021 Mar.

Authors

Affiliations

¹ Departments of Psychiatry & Behavioral Sciences and Sociology Duke University Medical Center Durham NC USA.
² Global Medical Affairs Radius Health, Inc. Waltham MA USA.
³ Department of Orthopaedics Orthopaedic Associates of Grand Rapids Research and Education Institute Grand Rapids MI USA.
⁴ Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatology The Cleveland Clinic Foundation Cleveland OH USA.
⁵ Epstein Health, LLC Woodcliff Lake NJ USA.
⁶ Adult Health CNS Proactive Orthopaedics Proactive Orthopaedics at Columbia Orthopaedic Groups LLP Columbia MO USA.
⁷ Osteoporosis Center of Delaware County Prospect Health Access Network Springfield PA USA.
⁸ Department of Medicine, Division of Bone and Mineral Diseases Washington University School of Medicine St Louis MO USA.
⁹ WCMG Rheumatology Western Connecticut Health Network Danbury CT USA.
¹⁰ Department of Medicine, Section of Endocrinology University of Chicago Chicago IL USA.
¹¹ Observational Research Adelphi Real World Bollington, Macclesfield UK.
¹² Biometrics Radius Health, Inc. Waltham, MA USA.
¹³ Health Economics and Outcomes Research Radius Health, Inc. Waltham, MA USA.

Abstract

Despite the availability of various osteoporosis treatments, adherence remains suboptimal. One contributing factor may be patient experience with therapy. This US, multicenter, combined retrospective chart review and patient questionnaire study included postmenopausal women at high risk for fracture and is the first study to describe real-world patient experience with abaloparatide (ABL) injection. Eight geographically diverse secondary care sites in the United States participated (n = 193). Mean ± SD age was 67.4 ±8.62 years. Most patients (86%) were satisfied with the ABL regimen, especially with ease of preparation (82%), ease of storage (87%), and storage convenience (89%), an attribute 83% of the patients thought was important. The majority of patients reported complete satisfaction with the ABL regimen allowing for their ability to conduct daily activities (85%) and convenience to fit into their daily schedule (84%). All reported taking ABL as directed, by injection in the lower abdomen, and 83% of patients reported medium or high adherence. Patients were satisfied with the needle size (76% completely satisfied), and 93% reported never deliberately missing a dose. Although injecting medication (18%) and higher out-of-pocket costs (17%) were deemed the most bothersome attributes, the majority (69%) noted their healthcare team understands how osteoporosis impacts their lives. In multivariable analyses, ease of preparation (OR = 2.62; 95% CI, 1.01-6.81; p = 0.048) and fracture history (OR = 1.72; 95% CI, 1.03-2.86; p = 0.037) were significantly associated with overall satisfaction. Ease of preparation was a predictor of higher satisfaction with treatment convenience (coefficient = 13.60; 95% CI, 8.08-19.12; p = 0.00). Remembering to take the medication was a significant predictor of self-reported adherence (OR = 16.66; 95% CI, 3.30-84.24; p = 0.001). In conclusion, the majority of patients were satisfied with ABL and found it convenient/easy to prepare and store. High self-reported adherence may be associated with positive patient experience including ease of use and adequate support from healthcare providers. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.

Keywords: ANABOLICS; HEALTH SERVICES RESEARCH; OSTEOPOROSIS.